Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Wet Shave products include razor handles and refillable blades, disposable shave products, and shaving gels and creams. Sun and Skin Care consists of sun care products, men’s and women’s grooming products, Billie women’s grooming products and personal wipe products. Feminine Care products include tampons, pads and liners. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
1999
6.7K+
LTM Revenue $2.2B
LTM EBITDA $301M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of November 2025, Edgewell reported last 12-month revenue of $2.2B and EBITDA of $301M.
In the same period, Edgewell generated $939M in LTM gross profit and $118M in net income.
See Edgewell valuation multiples based on analyst estimatesIn the most recent fiscal year, Edgewell reported revenue of $2.2B and EBITDA of $186M.
Edgewell expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Edgewell valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| Gross Profit | $939M | XXX | $925M | XXX | XXX | XXX |
| Gross Margin | 42% | XXX | 42% | XXX | XXX | XXX |
| EBITDA | $301M | XXX | $186M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 8% | XXX | XXX | XXX |
| EBIT | $218M | XXX | $196M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $118M | XXX | $25.4M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Edgewell has current market cap of $817M, and EV of $2.0B.
As of December 5, 2025, Edgewell's stock price is $18.
See Edgewell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $817M | XXX | XXX | XXX | XXX | $2.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialEdgewell's trades at 0.9x EV/Revenue multiple, and 7.7x EV/EBITDA.
See valuation multiples for Edgewell and 15K+ public compsAs of December 5, 2025, Edgewell has market cap of $817M and EV of $2.0B.
Equity research analysts estimate Edgewell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Edgewell has a P/E ratio of 6.9x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $817M | XXX | $817M | XXX | XXX | XXX |
| EV (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 6.7x | XXX | 7.7x | XXX | XXX | XXX |
| EV/EBIT | 9.2x | XXX | 8.9x | XXX | XXX | XXX |
| EV/Gross Profit | 2.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 6.9x | XXX | 10.2x | XXX | XXX | XXX |
| EV/FCF | 35.2x | XXX | 14.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEdgewell's last 12 month revenue growth is 2%
Edgewell's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Edgewell's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Edgewell's rule of X is 18% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Edgewell and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 13% | XXX | 13% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 18% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Edgewell acquired XXX companies to date.
Last acquisition by Edgewell was XXXXXXXX, XXXXX XXXXX XXXXXX . Edgewell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Edgewell founded? | Edgewell was founded in 1999. |
| Where is Edgewell headquartered? | Edgewell is headquartered in United States of America. |
| How many employees does Edgewell have? | As of today, Edgewell has 6.7K+ employees. |
| Who is the CEO of Edgewell? | Edgewell's CEO is Mr. Rod R. Little. |
| Is Edgewell publicy listed? | Yes, Edgewell is a public company listed on NYS. |
| What is the stock symbol of Edgewell? | Edgewell trades under EPC ticker. |
| When did Edgewell go public? | Edgewell went public in 2000. |
| Who are competitors of Edgewell? | Similar companies to Edgewell include e.g. Acme United, EZZ Life Science, Lavipharm, Sarantis Group. |
| What is the current market cap of Edgewell? | Edgewell's current market cap is $817M |
| What is the current revenue of Edgewell? | Edgewell's last 12 months revenue is $2.2B. |
| What is the current revenue growth of Edgewell? | Edgewell revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Edgewell? | Current revenue multiple of Edgewell is 0.9x. |
| Is Edgewell profitable? | Yes, Edgewell is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Edgewell? | Edgewell's last 12 months EBITDA is $301M. |
| What is Edgewell's EBITDA margin? | Edgewell's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Edgewell? | Current EBITDA multiple of Edgewell is 6.7x. |
| What is the current FCF of Edgewell? | Edgewell's last 12 months FCF is $56.9M. |
| What is Edgewell's FCF margin? | Edgewell's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Edgewell? | Current FCF multiple of Edgewell is 35.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.